The BGC training population is the most peptide-aware group in the country, and word of mouth here is fast, confident and lossy. The three things that reliably get lost in transmission are worth stating plainly, because they change what a sensible purchase looks like.
The first is the evidence class. BPC-157 has been studied in animal models, mostly rodent, for tendon and ligament work, gastrointestinal protection and wound healing under corticosteroid load. Angiogenesis, growth factor signalling and the nitric oxide pathway are the mechanisms the research literature describes. There is no human trial programme behind it, nothing is approved for human therapeutic use in the Philippines, and it is not on the US FDA list of bulk substances allowed for 503A compounding. The gym-floor version tends to arrive with the word preclinical quietly removed.
The second is that nobody notices a bad vial. Tendon complaints improve on their own schedule, recovery is subjective, and a four-week window is long enough for almost any story to form. That is precisely why BPC-157 is a common target for low-dose adulteration. A batch-matched third-party COA with an HPLC purity figure is the only part of this that is not guesswork.
The third is that the person who recommended it usually has no idea what they were working around, because they never had it imaged. BGC is one of the few districts where that is an easy problem to fix.